



Ref. No: HSCL / Stock-Ex/2024-25/93

Date: 13/01/2025

E-mail: [monika@himadri.com](mailto:monika@himadri.com)

<b>Ref: Listing Code: 500184</b> BSE Limited Department of Corporate Services P. J. Towers, 25 <sup>th</sup> Floor, Dalal Street, Mumbai- 400 001	<b>Ref: Listing Code: HSCL</b> National Stock Exchange of India Ltd Exchange Plaza, C-1, Block-G Bandra Kurla Complex, Bandra (E) Mumbai- 400 051
--	--

**Sub: Statement of deviation or variation in the use of proceeds of allotment of Equity Shares pursuant to exercise of warrants allotted on preferential basis**

Dear Sir/ Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Section IIIC of SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, it is hereby confirmed that there is no deviation or variation in the use of proceeds from the allotment of 25,000 (Twenty-five Thousand) equity shares on 21 October 2024 upon exercise of equal number of Warrants allotted on preferential basis, from the objects as stated in the Explanatory Statement to the Notice of the Postal Ballot dated 19 April 2024. Further, there is no category wise variation between projected utilisation of funds and the actual utilisation of funds.

A statement confirming that there is no deviation or variation in the utilisation of these proceeds, duly reviewed and approved by the Audit Committee at its meeting held on 13 January 2025 is enclosed.

This is for your information and taking on record.

Thanking You,

Yours faithfully,  
For Himadri Speciality Chemical Ltd

(Company Secretary &  
Compliance Officer)  
ACS: 29322

Enclosed: as above

**Himadri Speciality Chemical Ltd**  
(Formerly known as Himadri Chemicals & Industries Limited) CIN: L27106WB1987PLC042756  
Regd. Office: 23A, Netaji Subhas Road, 8th Floor, Kolkata – 700 001, India  
Corp. Office: 8, India Exchange Place, 2nd Floor, Kolkata – 700 001, India  
Tel: 91-33-2230-9953, 2230-4363, Fax: 91-33-2230-9051, Website: [www.himadri.com](http://www.himadri.com)



**Statement of Deviation / Variation in utilisation of funds raised**

<b>Name of listed entity</b>	Himadri Speciality Chemical Ltd
<b>Mode of Fund Raising</b>	Preferential Issue
<b>Date of Raising Funds (Date of exercising of warrants i.e receipt of the remaining 75% of the</b>	21 October 2024
<b>Amount Raised</b>	59,25,000/- (Rupees Fifty-Nine Lakhs Twenty-Five Thousands only) received upon receipt of payment at the rate of Rs. 237/- per warrant (being 75% of the issue price per warrant as “Warrant Exercise Price”) from the Warrant Holders.  The Company has allotted 25,000 (Twenty-five Thousands) Equity Shares of face value of Re. 1 each upon exercise of equal number of Warrants.  Refer Note
<b>Report filed for Quarter ended</b>	31 December 2024
<b>Monitoring Agency</b>	Applicable
<b>Monitoring Agency Name, if</b>	ICRA Limited
<b>Is there a Deviation / Variation in use of funds raised</b>	No
<b>If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders</b>	Not Applicable
<b>If Yes, Date of shareholder Approval</b>	Not Applicable
<b>Explanation for the Deviation / Variation</b>	Not Applicable
<b>Comments of the Audit Committee after Review</b>	No Comments
<b>Comments of the auditors, if any</b>	No Comments
<b>Objects for which funds have been raised</b>	<b>Capital Expenditure:</b> Capital expenditures for new green fields project or capital expenditure in its existing units and projects i.e. brown field expansion directly by the Company and/ or through its subsidiaries or joint ventures or associates for the growth of existing businesses or to enter into new business in line with the strategy of the Company.  <b>General Corporate Purposes:</b> General corporate purposes, which includes, <i>inter alia</i> , meeting ongoing general corporate exigencies and contingencies, expenses of the Company as applicable in such a manner and proportion as may be decided by the Board from time to time, and/or any other general purposes as may be permissible under applicable laws;



Where there has been a deviation. In the following table: Not Applicable

Original Object	Modified Object, if any	Original Allocation [Rs. Crore]	Modified allocation, if any	Funds Utilised [Rs. Crore]	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks, if any
<b>Capital Expenditure:</b> Capital expenditure for new green fields project or capital expenditure in its existing units and projects i.e. brown field expansion directly by the Company and/or through its subsidiaries or joint ventures or associates for the growth of existing businesses or to enter into new business in line with the strategy of the Company.	Not Applicable	256.82  (Utilisation of proceeds mentioned in postal ballot notice upto Rs 258 Crores)  Refer Note	Not Applicable	3.99  (Out of this Rs 3.40 Crore utilised upto the quarter ended 30 September 2024 and Rs 0.59 Crore utilised during the quarter ended 31 December 2024)	Nil	-
<b>General Corporate Purposes:</b> General corporate purposes, which includes, inter alia, meeting ongoing general corporate exigencies and contingencies, expenses of the Company as applicable in such a manner and proportion as may be decided by the Board from time to time, and/or any other general purposes as may be permissible under applicable laws;	Not Applicable	85  (Utilisation of proceeds mentioned in postal ballot notice Upto Rs 85 Crores)  Refer Note	Not Applicable	82.86  (Rs 82.86 Crore utilised upto the quarter ended 30 June 2024)	Nil	-
	<b>Total</b>	<b>341.82</b>		<b>86.85</b>		



**Note:**

- (i) On 20 March 2024, the Board of Directors of Himadri Speciality Chemical Ltd (“**Company**”), subject to the approval of the shareholders and such other regulatory or statutory approvals as may be required, approved issuance of 1,08,47,000 Warrants each convertible into, or exchangeable for, 1 (one) fully paid up equity share of the Company, having a face value of INR 1/- (Rupee one only) within a period of 18 (eighteen months) in accordance with the applicable laws (“**Warrants**”) at a price of Rs 316/- each payable in cash (“**Warrant Issue Price**”), aggregating upto Rs. 342.76 Crores to the Promoters and certain other identified persons.
- (ii) The Company obtained approval of the Members of the Company via special resolution passed through Postal Ballot on 19 April 2024.
- (iii) The Company obtained in-principle approval from BSE Limited and National Stock Exchange of India Limited *vide* their respective letters dated 06 May 2024 for 1,08,17,000 Warrants only. **Accordingly issue size was reduced from Rs 342.76 Crores to Rs 341.82 Crores.**
- (iv) Upon receipt of an amount aggregating to Rs. 85.45 Crores at the rate of Rs. 79/- per Warrant, being 25% of the issue price per Warrant as upfront payment (“**Warrant Subscription Price**”), the Share Issue & Allotment Committee of the Board of Directors of the Company, at its meeting held on 14 May 2024, has considered and approved the allotment of 1,08,17,000 Warrants at a price (including the Warrant Subscription Price and the Warrant Exercise Price) of Rs.316/- each payable in cash (“**Warrant Issue Price**”), aggregating upto Rs. 341.82 Crores (“**Total Issue Size**”) on preferential basis to the Promoters and certain other identified persons (“**Allottees**”).
- (v) Each Warrant, so allotted, is convertible into or exchangeable for one fully paid-up equity share of the Company having face value of Re. 1/- (Rupee One only) each in accordance with the provisions of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, on payment of the balance consideration of Rs. 237/- per Warrant (“**Warrant Exercise Price**”), being 75% of the issue price per Warrant from the Allottees pursuant to exercise of conversion option against each such warrant, within 18 months from the date of allotment of warrants.



(vi) **Amount Raised**

<b>Sl No</b>	<b>Particulars</b>	<b>Date of receipt of Funds</b>	<b>Amount raised and utilized (Rs in Crores)</b>	<b>Date of submission of Statement Pursuant to Regulation 32 to the Stock Exchanges</b>
1	Fund received from allotment of 1,08,17,000 warrants, each convertible into one equity share of face value of Re. 1 each (“Warrants”) upon receipt of Warrant Subscription Price at the rate of Rs. 79/- per warrant, being 25% of the issue price per warrant as upfront payment.	14 May 2024	85.45	16 July 2024
2	Fund received from allotment of 34,000 equity shares of face value of Re. 1 each upon conversion of equal number of Warrants on receipt of balance amount at the rate of Rs. 237/- per warrant (being 75% of the issue price per warrant as “Warrant Exercise Price”) from the warrant holder.	09 September 2024	0.81	16 October 2024
3	Fund received from allotment of 25,000 equity shares of face value of Re. 1 each upon conversion of equal number of Warrants on receipt of balance amount at the rate of Rs. 237/- per warrant (being 75% of the issue price per warrant as “Warrant Exercise Price”) from the warrant holder.	21 October 2024	0.59	13 January 2025 (Today)

Yours faithfully,  
For Himadri Speciality Chemical Ltd

(Company Secretary &  
Compliance Officer)  
ACS: 29322